Healthpeak said it reported diluted earnings per share of $0.21 for Q2 2024 (3 months ended June 30, 2024), compared with $0.09 a year earlier, with Nareit FFO of $0.44 per share, FFO as Adjusted of $0.45 per share, and AFFO of $0.39 per share.

1. 01

   Healthpeak said it reported diluted earnings per share of $0.21 for Q2 2024 (3 months ended June 30, 2024), compared with $0.09 a year earlier, with Nareit FFO of $0.44 per share, FFO as Adjusted of $0.45 per share, and AFFO of $0.39 per share.

2. 02

   The company said it revised its full-year 2024 diluted earnings per share outlook to a range of $0.16–$0.20 from $0.27–$0.31, and its FFO as Adjusted outlook to a range of $1.76–$1.80 per share from $1.77–$1.81.

3. 03

   Healthpeak said it sold $853 million of outpatient medical assets through Q2 and July 25, 2024 at a blended trailing cash capitalization rate of 6.8%, and that year-to-date dispositions were $1.2 billion.

4. 04

   Healthpeak said it repurchased 4.6 million shares from the beginning of Q2 through July 25, 2024 at a weighted average share price of $19.09, for a total of $88 million, and that in July it received board approval for a new $500 million share repurchase authorization effective through July 2026.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.